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modulating neurotransmission. Within the hypothalamic arcuate nucleus (ARC) astrocytes are 23 regulated by both positive and negative energy balance and express receptors for hormones that 24 influence satiety and hunger [8] [9] [10] [11] . Chemogenetic activation of these ARC astrocytes alters food 25 intake [11] [12] [13] . Since NTS astrocytes respond to vagal stimulation 14 , we hypothesised that they may be 26 involved in mediating satiety. Here we show that NTS astrocytes show plastic alterations in 27 morphology following excess food consumption and that chemogenetic activation of DVC astrocytes 28 causes a decrease in food intake, by recruiting an appetite-inhibiting circuit, without producing 29 aversion. These findings are the first using genetically-targeted manipulation of DVC astrocytes to 30 demonstrate their role in the brain's regulation of food intake. 31
In order to examine whether NTS astrocytes respond to changes in energy status we induced short-32 term positive energy balance by allowing mice to exclusively eat a high-fat chow for 12 hours during 33 the dark-phase. This paradigm induced a feeding binge when compared with standard chow-fed 34 mice ( Fig. 1a) . High-fat fed mice had a greater number of glial fibrillary acidic protein (GFAP)-35 immunoreactive astrocytes within the NTS when compared with controls, with the changes being 36 most pronounced in the NTS at the level of the AP (Fig. 1c-e) . GFAP-immunoreactive astrocytes in 37 the NTS adjacent to the AP of high-fat fed mice had greater morphological complexity, as assessed 38 by Sholl analysis 15, 16 , and a greater number of processes than those of standard chow fed controls 39 (Fig. 1f,g ). These findings suggest that NTS astrocytes show dynamic reactive changes to the acute 40 nutritional excess caused by consumption of a high-fat diet. 41
It is established that Gq-coupled designer receptors exclusively activated by designer drugs 42 (DREADDs) can be used to selectively activate astrocytes by driving increases in intracellular Ca 2+ , the 43 main signalling modality of these cells 11, [17] [18] [19] . We bilaterally injected the DVC of mice with adeno-44 associated viral (AAV) vectors containing hM3Dq_mCherry (DVC::GFAP hM3Dq mice) or mCherry 45 (DVC::GFAP mCherry mice) under the control of the human GFAP promoter (hGFAP) with the goal of 46 limiting expression to DVC astrocytes (Fig. 2a,b) . Examining mCherry immunoreactivity showed 47 strong expression in the DVC (Fig. 2c) . The mCherry expressing cells were immunopositive for GFAP 48 (Figure 2d ) but not the neuronal marker NeuN (Fig. 2e) indicating cell type-specificity.
Mice typically eat most of their food during the dark-phase. Chemogenetic activation of the 50 transduced astrocytes in DVC::GFAP hM3Dq mice (clozapine-N-oxide CNO; 0.3.mg/kg, i.p immediately 51 prior to onset of the dark-phase) produced an 83.9% reduction in food intake (4 hours after 52 injection) compared to saline control (Fig 2f) . This anorectic effect lasted approximately 6 hours 53 after which the rate of food intake was not significantly different to the control group (Fig. 2g) . Body-54 weight, measured 8 hours after lights-off was reduced by 4.4% on the day of CNO injection 55 compared with the day of saline injection ( Fig. 2h ). In DVC::GFAP mCherry mice the same CNO injection 56 protocol had no effect on dark-phase food intake, feeding rate, or body-weight ( Fig. 2i-k) . Following 57 i.p. injection of CNO, both food intake and food seeking behaviour were lower in DVC::GFAP hM3Dq 58 mice compared with DVC::GFAP mCherry mice ( Supplementary Fig. 1a-c ). This suggests that the reduced 59 food intake is a result of suppressed drive to feed rather than reflecting a motor impairment of 60 feeding, such as may be anticipated as a result of activation of astrocytes in the hypoglossal nucleus 61 (HGN) disrupting tongue movement. 62
To evaluate whether chemogenetic activation of DVC astrocytes was still sufficient to impact feeding 63 when there was an increased drive to eat, we utilised a fast-induced re-feeding paradigm. CNO 64 injection (0.3.mg/kg i.p.) prior to reintroduction of food after a 12 hour fast lowered cumulative food 65 intake in DVC::GFAP hM3Dq mice compared with DVC::GFAP mCherry controls (Fig. 2l) . During the first hour 66 of refeeding, the rate of food intake was 62.7% lower in DVC::GFAP hM3Dq mice, compared with 67 DVC::GFAP mCherry controls (measured after 1 hour), indicating that activation of DVC astrocytes was 68 sufficient to acutely supress the drive to eat induced by fasting (Fig. 2m) . No compensatory/rebound 69 hyperphagia was observed in DVC::GFAP hM3Dq mice in the 24 hours following CNO injection ( Fig.  70 2l,m). In line with the differences in food intake, DVC::GFAP mCherry mice recovered more of their body 71 weight lost as a result of the fast within 8 hours of food being reintroduced than DVC::GFAP hM3Dq 72 mice (Fig. 2n) . 73
Reductions in food intake in mice can be indicative of malaise and/or aversion 20 . To test whether 74 DVC astrocyte activation is aversive we used a conditioned place assay (Fig 3a) . During initial 75 assessment, prior to conditioning, neither DVC::GFAP hM3Dq nor DVC::GFAP mCherry mice showed a 76 preference for either chamber (Fig 3c,d) . Consistent with an absence of aversion/negative salience 77 associated with malaise, following conditioning (pairing each side of the apparatus with either saline 78 or i.p. CNO injection) mice still showed no preference for or avoidance of a particular side of the 79 apparatus ( Fig. 3b-d) . Furthermore, during conditioning trials there was no statistically significant 80 difference in total distance travelled following saline or CNO treatment in the DVC::GFAP hM3Dq or 81 DVC::GFAP mCherry groups suggesting that CNO-mediated DREADD activation did not cause malaise, 82 sedation or impact locomotion (Fig. 3e,f 4a-e), and the downstream target of NTS neurons the lateral parabrachial nucleus (lPBN) (Fig. 4f-i) . 88
However in the paraventricular nucleus of the hypothalamus (PVH), another projection target of 89 satiety signalling NTS neurons 5, 21 , there was no difference in the number of c-FOS expressing cells 90 between groups (Fig. 4j-m) . This indicates that CNO activates astrocytes in DVC::GFAP hM3Dq mice 91 which leads to the recruitment of local and downstream neuronal circuitry implicated in regulating 92 energy homeostasis 22, 23 . 93
In this study we have shown that astrocytes in the NTS react to excess intake of an energy dense 94 food by upregulating GFAP expression and show morphological plasticity. Furthermore, DREADD-95 mediated activation of astrocytes in the DVC causes a potent but reversible decrease in food intake, 96 associated with activation of local and distant neuronal circuits, without inducing emotionally salient 97 associations. This evidence supports the hypothesis that these astrocytes are involved in a 98 homeostatic response to increases in food intake and their activation acts to drive a counter-acting 99 decrease in food intake to restore energy balance. 100
Astrocytes of the hypothalamic arcuate nucleus (ARC) have also been implicated in the regulation of 101 food intake 8 . In the hypothalamus these glia are activated by short-term energy imbalance and 102 direct manipulation of their activity using DREADDs alters food intake 8, 11, 12, 24 . The first study using 103
DREADDs to activate ARC astrocytes from Yang and colleagues observed a decrease in food intake 104 during the dark-phase of a smaller magnitude and shorter time duration than we observed with 105 DVC-astrocyte activation 12 . However a second group, Chen and colleagues, observed the converse 106 effect: an increase in dark-phase feeding with a short (~1hr post injection) time course 11 . Both 107 studies reported that CNO injection drove feeding behaviour in the light-phase but again Chen et al 108
showed an immediate (within 30 min of injection) effect while Yang et al showed a delayed effect 109 (increased cumulative intake at 9 hrs after injection). It appears that chemogenetic DVC astrocyte 110 activation has effects on feeding distinct from those described following comparable studies 111 examining ARC astrocyte activation with respect to the magnitude, direction and onset/duration of 112 the effect. 113
Our study builds upon evidence showing astrocytes of the NTS sense hormonal satiety signals 25 and 114 are involved in integration of vagal neurotransmission 14 , but importantly extends these studies by 115 using direct, inducible manipulation of these cells and studying behaviour in freely moving animals. Furthermore, in rats, NTS astrocytes take up exendin-4, an agonist of the GLP-1R. Metabolic 122 inhibition of astrocytes neighbouring the 4V abolishes the anorexigenic effect of exendin-4, 123 suggesting these cells are responsible for mediating the effect 25 . Two studies that manipulate 124 inflammatory nuclear factor kappa b (NF-κB) signalling in all GFAP-expressing astrocytes report 125 feeding phenotypes, namely increased initial intake of a high-fat diet following initial exposure and 126 resistance to the obesity phenotype when already on a high-fat diet 8, 26 . Although these studies 127 attribute the observed effects to astrocytes of the hypothalamus the contribution of NTS astrocytes, 128 identified here as responsive to high-fat diet intake, cannot be ruled out. 129
The induction of c-FOS-immunoreactivity in a distal target, namely the lPBN, following CNO injection 130 Dark-phase high-fat feeding studies and histology
236
Two independent cohorts of mice (aged 16 weeks) were individually housed for 4-5 days. At lights-237 off, standard chow was substituted for high-fat chow (D12492, TestDiet, USA) with control animals 238 maintained on standard chow (EURodent diet). 12 -14 hours later mice were transcardially perfused 239 under deep sodium pentobarbital anaesthesia with heparinised 0.9% saline followed by 4% 240 paraformaldehyde. Brains were post fixed in 4% paraformaldehyde for 4-6 hours before being 241 transferred to 30% sucrose in phosphate buffered saline (PBS). 30 μm coronal sections of the 242 hindbrain were taken with a freezing microtome (Bright instruments, UK) in 4 series. One series was 243 taken and washed 3 times in 0.01M PBS then incubated for 1 hr at room temperature in 0.01M PBS 244 with 5% normal donkey serum (Sigma, UK) and 0.3% triton X-100 (T8787, Sigma, UK). Following this, 245 sections were incubated overnight at 4°C in mouse anti-GFAP (MAB360, Millipore, UK) diluted 246 1:5000 in 0.01M PBS with 1% normal donkey serum and 0.3% triton X-100. Sections were washed 8 247 times in 0.01M PBS and incubated in for 1 hr at room temperature donkey anti-mouse Alexa Fluor 248 568 (A10037, Invitrogen, UK) diluted 1:500 in 0.01M PBS with 0.3% triton X-100. Sections were 249 washed 8 times in 0.01M PBS, mounted onto glass slides and coverslipped with fluoroshield 250 mounting medium with DAPI (ab104139, Abcam, UK). Images for counting were acquired at 10X 251 magnification on a fluorescence microscope (DM 4000, Leica, Germany). NTS subdivisions (Fig. 1e)  252 were calculated as follows: rostral = -7.08mm --7.2mm from Bregma, postremal = -7.32mm --253 7.64mm from Bregma, cadual = -7.76mm --8mm from Bregma. Images for morphological analysis 254 were acquired at 20X on a confocal microscope (DMi8, Leica, Germany). Images were analysed in 255 FIJI 30 (NIH, USA) using the cell counter, simple neurite tracer and Sholl analysis plugins 16 . For tracing, 256 5 cells per image from 2 images per animal were randomly selected for tracing and morphological 257 analysis. The investigator was blinded to the diet of the mice during staining, acquisition and 258
analysis. 259
Mice (8-12 weeks) were injected with adeno-associated viral vectors in the NTS as described 261 previously 4 . The vectors used were AAV5/2-hGFAP-hM3D(Gq)_mCherry (v97-5, titre ≥ 7.5x10 12 viral 262 genomes/ml; University of Zurich Viral Vector Facility, Switzerland) and AAV5/2-hGFAP-mCherry 263 (custom preparation, titre 3.89x10 13 viral genomes/ml; ViGene Biosciences, USA) and were diluted 264 1:1 in sterile PBS prior to injection. In brief, mice were deeply anaesthetised with ketamine (70 265 mg/kg) and medetomidine (0.5 mg/kg) and placed in a stereotaxic frame (David Kopf Instruments, 266 USA) with the nose angled down by 20°. An incision from the crest of the skull to the nape of the 267 neck was made with a scalpel, the muscles were parted and the atlanato-occipital membrane 268 removed to expose the surface of the brainstem. Injections were from by a pulled glass pipette 269 attached to an injection system (Neurostar, Germany) mounted on the stereotaxic frame at an angle 270 of 35° to the vertical, tip facing rostral. The pipette was inserted 400 μm lateral to the midline at the 271 level of calamus scriptorius to a depth of 1mm. Four injections of 180 nl were made at depths of -1 272 mm, -750 μm, -500 μm and -250 μm respectively at a rate of 100 nl/minute. The pipette was left in 273 place for 1 minute after each injection. These injections were then repeated on the contralateral 274 side. Mice were injected with atipamezole (1 mg/kg) and buprenorphine (0.1 mg/kg) for anaesthetic 275 reversal and analgesia respectively and transferred to a heated cage to recover. Following surgery 276 mice were individually housed for the duration of the experiment. The investigator was blinded to 277 mouse group allocations for all of the subsequent experiments. 278
Measurement of feeding

279
At 4-8 weeks following surgery, mice were acclimatised to experimenter handling and 280 intraperitoneal injections of saline for 4 days. Mice were given an intraperitoneal (i.p.) injection of 281 saline 15-30 minutes prior to the beginning of the dark-phase. Food was removed at the time of 282 injection and returned to cages at the onset of the dark-phase. Food intake was measured at 2, 4, 6, 283 12 and 24 hours after lights-off and body weight was measured 8 hours after lights-off. The following 284 day mice were given an i.p. injection of CNO (0.3 mg/kg, 4936, Tocris, UK) and food intake and body 285 weight measured at the same time points. For the fast-refeed experiment food was removed from 286 cages at the beginning of the dark-phase and 15-30 minutes prior to the light phase animals were 287 injected with 0.3 mg/kg CNO i.p. Food was returned to cages at the onset of the light phase and food 288 intake was measured 1, 2, 4, 6, 8, 12 and 24 hours after lights-on. Body weight was measured prior 289 to food being removed and at 8 hours after the reintroduction of food. 290
Conditioned place preference assay 291 For conditioned place preference testing an apparatus consisting of 2 chambers joined by a clear 292 plastic external corridor (see figure 3b ) was used. The left chamber had horizontal black and white 293 stripes on the walls and a perforate floor and the right chamber had vertical black and white stripes 294 on the walls and a floor with horizontal grating. On the first day mice were given 20 minutes of free 295 access to the whole apparatus. This session was recorded using a video camera and used to 296 determine initial preferences. On the second day mice were assigned to receive an i.p. injection of 297 either 0.3 mg/kg CNO or an equivalent volume of saline 15 minutes prior to being placed in either 298 the left or right chamber for 45 minutes, with the access to the second chamber blocked. On the 299 third day mice received the opposite treatment with their access restricted to the alternate 300 chamber, compared to the second day. On the fourth and final day mice were given free access to 301 the whole apparatus for 30 minutes. Again this session was recorded and used to determine 302 conditioned preference. Recorded sessions were analysed offline using Ethovision XT (Noldus, 303 Netherlands) tracking software. 304
Evaluation of DREADD-induced c-FOS activation and histological analysis
305
Mice were injected i.p. with 0.3 mg/kg CNO and food removed from the cage. 2-3 hours later mice 306 were transcardially perfused as described above. 30 µm coronal sections were taken and stained as 307 described above with primary antibodies against GFAP, mCherry, NeuN and c-FOS (Table 1) and 308 appropriate secondary antibodies donkey anti-mouse Alexa Fluor488, donkey anti-goat Alexa 309
Fluor594 and donkey anti-rabbit Alexa Fluor488 (Invitrogen, UK). For double immunohistochemistry 310 mCherry staining was performed first followed by GFAP or NeuN. Images were acquired on a 311 confocal microscope (DMi8, Leica, Germany). For c-FOS quantification, images were analysed in FIJI 312 with the cell counter plugin. 313 phase. l, Cumulative food intake (Two-way ANOVA, Genotype, p=0.01, F (1,10) =10.03; Time, p<0.0001, 384 F (7, 70) =310.5; interaction, p=0.0053, F (7,70) =3.20, Sidak's post-hoc test). m, Rate of food intake (Two-385 way ANOVA, Genotype, p=0.007, F (1, 10) =11.4; Time, p<0.0001, F (6, 60) =18.55; interaction, p<0.0001, 386 F (6,60) =8.35, Sidak's post-hoc test). n, Change in body weight from before fasting to 8 hours after 387 refeeding (-.017 ± 0.21 vs -1.47 ± 0.48 g, p=0.024 unpaired t-test). * = p<0.05, ** = p<0.01, **** = 388 p<0.0001. AP = area postrema, DMX = dorsal motor nucleus of the vagus, HGN = hypoglossal 389 nucleus, NTS = nucleus of the solitary tract. 390
